No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Times cited: 11
Treating multiple sclerosis in the natalizumab era: Risks, benefits, clinical decision making, and a comparison between North American and European Union practices.
Reviews in Neurological Diseases.
Times cited: 5